
<div id="jpedal" style="overflow: hidden; position: relative; width: 909px; height: 1212px;">
<style type="text/css" >
.t {
	-webkit-transform-origin: top left;
	-moz-transform-origin: top left;
	-o-transform-origin: top left;
	-ms-transform-origin: top left;
	-webkit-transform: scale(0.25);
	-moz-transform: scale(0.25);
	-o-transform: scale(0.25);
	-ms-transform: scale(0.25);
	z-index: 2;
	position:absolute;
	white-space:nowrap;
	overflow:visible;
}
</style>
<style type="text/css" >

#t1_1{left:72px;top:242px;word-spacing:7.9px;}
#t2_1{left:72px;top:307px;letter-spacing:-0.2px;word-spacing:11.4px;}
#t3_1{left:72px;top:323px;letter-spacing:0.7px;word-spacing:21.1px;}
#t4_1{left:72px;top:339px;letter-spacing:-0.3px;word-spacing:2.2px;}
#t5_1{left:72px;top:357px;word-spacing:12.1px;}
#t6_1{left:72px;top:374px;word-spacing:4.1px;}
#t7_1{left:72px;top:401px;word-spacing:4.3px;}
#t8_1{left:72px;top:435px;word-spacing:4.3px;}
#t9_1{left:72px;top:452px;word-spacing:-0.8px;}
#ta_1{left:72px;top:470px;word-spacing:9.2px;}
#tb_1{left:72px;top:488px;word-spacing:-0.3px;}
#tc_1{left:72px;top:505px;word-spacing:3.6px;}
#td_1{left:72px;top:523px;word-spacing:-1.2px;}
#te_1{left:72px;top:540px;word-spacing:15px;}
#tf_1{left:72px;top:558px;word-spacing:7.9px;}
#tg_1{left:72px;top:576px;word-spacing:5.8px;}
#th_1{left:72px;top:593px;word-spacing:0.6px;}
#ti_1{left:72px;top:611px;word-spacing:4.9px;}
#tj_1{left:72px;top:629px;word-spacing:11.7px;}
#tk_1{left:72px;top:646px;word-spacing:-0.6px;}
#tl_1{left:72px;top:664px;word-spacing:9.4px;}
#tm_1{left:72px;top:682px;word-spacing:-2.4px;}
#tn_1{left:72px;top:699px;word-spacing:4.4px;}
#to_1{left:91px;top:717px;word-spacing:9.5px;}
#tp_1{left:301px;top:717px;}
#tq_1{left:312px;top:717px;word-spacing:9.4px;}
#tr_1{left:72px;top:735px;word-spacing:1.9px;}
#ts_1{left:310px;top:735px;}
#tt_1{left:320px;top:735px;word-spacing:1.9px;}
#tu_1{left:72px;top:752px;word-spacing:28.9px;}
#tv_1{left:72px;top:770px;word-spacing:20.6px;}
#tw_1{left:72px;top:788px;word-spacing:23.6px;}
#tx_1{left:217px;top:788px;}
#ty_1{left:228px;top:788px;word-spacing:19.6px;}
#tz_1{left:72px;top:805px;}
#t10_1{left:77px;top:805px;}
#t11_1{left:88px;top:805px;letter-spacing:-0.2px;word-spacing:11.3px;}
#t12_1{left:72px;top:823px;letter-spacing:-0.2px;word-spacing:17.3px;}
#t13_1{left:72px;top:841px;letter-spacing:-0.2px;word-spacing:-0.8px;}
#t14_1{left:72px;top:858px;letter-spacing:-0.2px;word-spacing:0.1px;}
#t15_1{left:328px;top:858px;}
#t16_1{left:339px;top:858px;letter-spacing:-0.2px;word-spacing:0.3px;}
#t17_1{left:72px;top:876px;letter-spacing:-0.3px;word-spacing:11.5px;}
#t18_1{left:72px;top:894px;letter-spacing:-0.3px;word-spacing:27px;}
#t19_1{left:72px;top:911px;letter-spacing:-0.3px;word-spacing:18.2px;}
#t1a_1{left:72px;top:929px;letter-spacing:-0.2px;word-spacing:6px;}
#t1b_1{left:72px;top:947px;letter-spacing:-0.2px;word-spacing:2.9px;}
#t1c_1{left:72px;top:964px;letter-spacing:-0.3px;word-spacing:1.4px;}
#t1d_1{left:72px;top:982px;letter-spacing:-0.3px;word-spacing:-1.6px;}
#t1e_1{left:72px;top:999px;letter-spacing:-0.3px;word-spacing:2.3px;}
#t1f_1{left:72px;top:1031px;word-spacing:4.3px;}
#t1g_1{left:72px;top:1049px;word-spacing:11.6px;}
#t1h_1{left:72px;top:1067px;word-spacing:12.1px;}
#t1i_1{left:72px;top:1084px;word-spacing:10.8px;}
#t1j_1{left:465px;top:306px;letter-spacing:0.5px;word-spacing:9.2px;}
#t1k_1{left:465px;top:324px;letter-spacing:0.5px;word-spacing:14.2px;}
#t1l_1{left:465px;top:342px;letter-spacing:0.5px;word-spacing:0.9px;}
#t1m_1{left:465px;top:359px;letter-spacing:0.5px;word-spacing:7.7px;}
#t1n_1{left:465px;top:377px;letter-spacing:0.5px;word-spacing:15.5px;}
#t1o_1{left:465px;top:395px;letter-spacing:0.5px;word-spacing:11.3px;}
#t1p_1{left:465px;top:412px;letter-spacing:0.5px;word-spacing:1.8px;}
#t1q_1{left:465px;top:430px;letter-spacing:0.6px;word-spacing:2.5px;}
#t1r_1{left:483px;top:448px;letter-spacing:0.5px;word-spacing:7.7px;}
#t1s_1{left:465px;top:465px;letter-spacing:-0.1px;word-spacing:19.3px;}
#t1t_1{left:465px;top:483px;letter-spacing:-0.3px;word-spacing:15.4px;}
#t1u_1{left:465px;top:501px;letter-spacing:-0.2px;word-spacing:8.7px;}
#t1v_1{left:465px;top:518px;letter-spacing:-0.2px;word-spacing:1.6px;}
#t1w_1{left:652px;top:518px;letter-spacing:-0.4px;}
#t1x_1{left:670px;top:518px;letter-spacing:-0.2px;word-spacing:1.5px;}
#t1y_1{left:813px;top:518px;letter-spacing:-0.4px;}
#t1z_1{left:465px;top:536px;letter-spacing:0.9px;}
#t20_1{left:465px;top:554px;letter-spacing:-0.3px;word-spacing:9.4px;}
#t21_1{left:465px;top:571px;letter-spacing:-0.3px;word-spacing:6.6px;}
#t22_1{left:465px;top:589px;letter-spacing:-0.2px;word-spacing:18.7px;}
#t23_1{left:465px;top:607px;letter-spacing:-0.3px;word-spacing:5.8px;}
#t24_1{left:465px;top:624px;letter-spacing:-0.2px;word-spacing:10px;}
#t25_1{left:465px;top:642px;letter-spacing:-0.2px;word-spacing:2.3px;}
#t26_1{left:758px;top:642px;letter-spacing:-0.4px;}
#t27_1{left:776px;top:642px;}
#t28_1{left:483px;top:660px;word-spacing:6.9px;}
#t29_1{left:465px;top:677px;word-spacing:-1.8px;}
#t2a_1{left:465px;top:695px;word-spacing:6.5px;}
#t2b_1{left:465px;top:713px;word-spacing:3.3px;}
#t2c_1{left:465px;top:730px;word-spacing:14.5px;}
#t2d_1{left:596px;top:730px;}
#t2e_1{left:604px;top:730px;word-spacing:14.3px;}
#t2f_1{left:465px;top:748px;word-spacing:23.9px;}
#t2g_1{left:465px;top:766px;word-spacing:21.4px;}
#t2h_1{left:465px;top:783px;word-spacing:4.5px;}
#t2i_1{left:465px;top:801px;}
#t2j_1{left:534px;top:801px;}
#t2k_1{left:552px;top:801px;word-spacing:-1.8px;}
#t2l_1{left:465px;top:818px;word-spacing:4.6px;}
#t2m_1{left:465px;top:836px;}
#t2n_1{left:473px;top:836px;}
#t2o_1{left:481px;top:836px;word-spacing:-1.5px;}
#t2p_1{left:465px;top:854px;word-spacing:4.4px;}
#t2q_1{left:483px;top:871px;letter-spacing:-0.3px;word-spacing:4px;}
#t2r_1{left:465px;top:889px;letter-spacing:-0.2px;word-spacing:-0.4px;}
#t2s_1{left:465px;top:907px;letter-spacing:-0.3px;word-spacing:-4.1px;}
#t2t_1{left:465px;top:924px;letter-spacing:-0.3px;word-spacing:-2.8px;}
#t2u_1{left:465px;top:942px;letter-spacing:-0.2px;word-spacing:4.2px;}
#t2v_1{left:465px;top:960px;letter-spacing:-0.3px;word-spacing:-0.9px;}
#t2w_1{left:465px;top:977px;}
#t2x_1{left:500px;top:977px;letter-spacing:-0.4px;}
#t2y_1{left:518px;top:977px;letter-spacing:-0.2px;word-spacing:18.2px;}
#t2z_1{left:465px;top:995px;letter-spacing:-0.3px;word-spacing:9.1px;}
#t30_1{left:465px;top:1013px;letter-spacing:-0.3px;word-spacing:10.9px;}
#t31_1{left:465px;top:1030px;letter-spacing:-0.2px;word-spacing:3.3px;}
#t32_1{left:695px;top:1030px;letter-spacing:-0.3px;}
#t33_1{left:712px;top:1030px;letter-spacing:-0.2px;word-spacing:3.2px;}
#t34_1{left:465px;top:1048px;letter-spacing:-0.2px;word-spacing:2.6px;}
#t35_1{left:546px;top:1048px;}
#t36_1{left:557px;top:1048px;letter-spacing:-0.2px;word-spacing:2.3px;}
#t37_1{left:465px;top:1066px;letter-spacing:-0.2px;word-spacing:-0.1px;}
#t38_1{left:572px;top:1066px;}
#t39_1{left:583px;top:1066px;letter-spacing:-0.2px;word-spacing:-0.4px;}
#t3a_1{left:683px;top:1066px;}
#t3b_1{left:694px;top:1066px;letter-spacing:-0.2px;word-spacing:-0.4px;}
#t3c_1{left:465px;top:1083px;letter-spacing:-0.2px;word-spacing:-0.7px;}
#t3d_1{left:316px;top:50px;letter-spacing:6.6px;word-spacing:4.4px;}
#t3e_1{left:72px;top:94px;letter-spacing:5.4px;word-spacing:4.8px;}
#t3f_1{left:72px;top:111px;letter-spacing:5.5px;word-spacing:5.1px;}

.s6_1{
	FONT-SIZE: 51.8px;
	FONT-FAMILY: CDIAEN-AdvP4C4E741;
	color: rgb(0,0,0);
}

.s5_1{
	FONT-SIZE: 51.8px;
	FONT-FAMILY: CDIAEM-AdvP4DF60F1;
	color: rgb(0,0,0);
}

.s8_1{
	FONT-SIZE: 51.8px;
	FONT-FAMILY: CDIAFO-AdvP7DA61;
	color: rgb(0,0,0);
}

.s10_1{
	FONT-SIZE: 48.7px;
	FONT-FAMILY: CDIAFP-AdvP8CAA1;
	color: rgb(0,0,0);
}

.s9_1{
	FONT-SIZE: 39px;
	FONT-FAMILY: CDIAEK-AdvP4DF60E1;
	color: rgb(0,104,156);
}

.s3_1{
	FONT-SIZE: 51.8px;
	FONT-FAMILY: CDIAEK-AdvP4DF60E1;
	color: rgb(0,0,0);
}

.s4_1{
	FONT-SIZE: 51.8px;
	FONT-FAMILY: CDIAEL-AdvP4C4E511;
	color: rgb(0,0,0);
}

.s2_1{
	FONT-SIZE: 51.8px;
	FONT-FAMILY: CDIAEJ-AdvP4DF6141;
	color: rgb(0,0,0);
}

.s1_1{
	FONT-SIZE: 91.3px;
	FONT-FAMILY: CDIAEJ-AdvP4DF6141;
	color: rgb(0,0,0);
}

.s7_1{
	FONT-SIZE: 51.8px;
	FONT-FAMILY: CDIAEK-AdvP4DF60E1;
	color: rgb(0,104,156);
}

.v1_1{
	-webkit-transform: scale(0.259, 0.25);
	-ms-transform: scale(0.259, 0.25);
	-moz-transform: scale(0.259, 0.25);
	-o-transform: scale(0.259, 0.25);
}

#form1_1{	border-style:none;	z-index:2;	position: absolute;	left:500px;	top:979px;	width:19px;	height:14px;	text-align:left;	background: transparent;	font:normal 10px Arial, Helvetica, sans-serif;}
#form1_2{	border-style:none;	z-index:2;	position: absolute;	left:758px;	top:643px;	width:19px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form1_3{	border-style:none;	z-index:2;	position: absolute;	left:651px;	top:520px;	width:20px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form1_4{	border-style:none;	z-index:2;	position: absolute;	left:533px;	top:802px;	width:20px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form1_5{	border-style:none;	z-index:2;	position: absolute;	left:694px;	top:1031px;	width:20px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form1_6{	border-style:none;	z-index:2;	position: absolute;	left:811px;	top:520px;	width:20px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form1_7{	border-style:none;	z-index:2;	position: absolute;	left:315px;	top:51px;	width:274px;	height:11px;	text-align:left;	background: transparent;	font:normal 7px Arial, Helvetica, sans-serif;}

</style>
<style id="fonts1" type="text/css" >

@font-face {
	font-family: CDIAEJ-AdvP4DF6141;
	src: url("1/fonts/CDIAEJ-AdvP4DF614.woff") format("woff");
}

@font-face {
	font-family: CDIAEN-AdvP4C4E741;
	src: url("1/fonts/CDIAEN-AdvP4C4E74.woff") format("woff");
}

@font-face {
	font-family: CDIAFP-AdvP8CAA1;
	src: url("1/fonts/CDIAFP-AdvP8CAA.woff") format("woff");
}

@font-face {
	font-family: CDIAFO-AdvP7DA61;
	src: url("1/fonts/CDIAFO-AdvP7DA6.woff") format("woff");
}

@font-face {
	font-family: CDIAEK-AdvP4DF60E1;
	src: url("1/fonts/CDIAEK-AdvP4DF60E.woff") format("woff");
}

@font-face {
	font-family: CDIAEM-AdvP4DF60F1;
	src: url("1/fonts/CDIAEM-AdvP4DF60F.woff") format("woff");
}

@font-face {
	font-family: CDIAEL-AdvP4C4E511;
	src: url("1/fonts/CDIAEL-AdvP4C4E51.woff") format("woff");
}

</style>
<div id="t1_1" class="t v1_1 s1_1">Words of Wisdom</div>
<div id="t2_1" class="t v1_1 s2_1">Re: Incidence of Prostate Cancer in Hypogonadal Men</div>
<div id="t3_1" class="t v1_1 s2_1">Receiving Testosterone Therapy: Observations from</div>
<div id="t4_1" class="t v1_1 s2_1">5-Year Median Followup of 3 Registries</div>
<div id="t5_1" class="t v1_1 s3_1">Haider A, Zitzmann M, Doros G, Isbarn H, Hammerer P,</div>
<div id="t6_1" class="t v1_1 s3_1">Yassin A</div>
<div id="t7_1" class="t s3_1">J Urol 2015;193:80–6</div>
<div id="t8_1" class="t s2_1">Experts’ summary:</div>
<div id="t9_1" class="t s3_1">The recent publication by Haider and colleagues identifies the</div>
<div id="ta_1" class="t s3_1">incidence of prostate cancer in hypogonadal men receiving</div>
<div id="tb_1" class="t s3_1">testosterone supplementation therapy (TST). This prospective</div>
<div id="tc_1" class="t s3_1">study involved three ongoing parallel registries: two cohorts</div>
<div id="td_1" class="t s3_1">of patients presenting for erectile dysfunction or hypogonadal</div>
<div id="te_1" class="t s3_1">symptoms at private urologic practices (cohorts 1 and 2)</div>
<div id="tf_1" class="t s3_1">and one cohort of patients presenting for hypogonadism or</div>
<div id="tg_1" class="t s3_1">Klinefelter syndrome at an academic urology and andrology</div>
<div id="th_1" class="t s3_1">clinic (cohort 3). The mean follow-up was approximately 5 yr</div>
<div id="ti_1" class="t s3_1">for all three cohorts. In total, 1023 men with hypogonadism</div>
<div id="tj_1" class="t s3_1">received TST and had initial screening for prostate cancer,</div>
<div id="tk_1" class="t s3_1">which included prostate-specific antigen (PSA) measurement,</div>
<div id="tl_1" class="t s3_1">digital rectal examination, and transrectal ultrasonography.</div>
<div id="tm_1" class="t s3_1">The three studies followed patients using these modalities at a</div>
<div id="tn_1" class="t s3_1">minimum of twice a year.</div>
<div id="to_1" class="t v1_1 s3_1">In all cohorts, baseline PSA was</div>
<div id="tp_1" class="t v1_1 s4_1">&lt;</div>
<div id="tq_1" class="t v1_1 s3_1">4 ng/ml, and if PSA</div>
<div id="tr_1" class="t v1_1 s3_1">increased abruptly or gradually rose t</div>
<div id="ts_1" class="t v1_1 s4_1">&gt;</div>
<div id="tt_1" class="t v1_1 s3_1">4 ng/ml, a prostate</div>
<div id="tu_1" class="t v1_1 s3_1">biopsy was performed in accordance with European</div>
<div id="tv_1" class="t v1_1 s3_1">Association of Urology guidelines. The prostate cancer</div>
<div id="tw_1" class="t v1_1 s3_1">incidence was 2.3% (</div>
<div id="tx_1" class="t v1_1 s5_1">n</div>
<div id="ty_1" class="t v1_1 s3_1">= 6/261) in cohort 1 and 1.5%</div>
<div id="tz_1" class="t v1_1 s3_1">(</div>
<div id="t10_1" class="t v1_1 s5_1">n</div>
<div id="t11_1" class="t v1_1 s3_1">= 5/340) in cohort 2. There were no cases of prostate</div>
<div id="t12_1" class="t v1_1 s3_1">cancer in cohort 3. Of note, there were three cases of</div>
<div id="t13_1" class="t v1_1 s3_1">Gleason 5, seven cases of Gleason 6, and one case of Gleason</div>
<div id="t14_1" class="t v1_1 s3_1">7 disease. There was no report of Gleason</div>
<div id="t15_1" class="t v1_1 s6_1">±</div>
<div id="t16_1" class="t v1_1 s3_1">8. These rates of</div>
<div id="t17_1" class="t v1_1 s3_1">prostate cancer incidence are lower than those from the</div>
<div id="t18_1" class="t v1_1 s3_1">Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer</div>
<div id="t19_1" class="t v1_1 s3_1">screening trial and the European Randomized Study of</div>
<div id="t1a_1" class="t v1_1 s3_1">Prostate Cancer (ERSPC), which have screened 38 343 and</div>
<div id="t1b_1" class="t v1_1 s3_1">72 891 patients and reported incidences of 7.35% and 9.6%,</div>
<div id="t1c_1" class="t v1_1 s3_1">respectively. These findings suggest that men with hypogo-</div>
<div id="t1d_1" class="t v1_1 s3_1">nadism receiving TST are not at additional risk of developing</div>
<div id="t1e_1" class="t v1_1 s3_1">prostate cancer when compared to the general population.</div>
<div id="t1f_1" class="t s2_1">Experts’ comments:</div>
<div id="t1g_1" class="t s3_1">Progression of prostate cancer depends to some extent on</div>
<div id="t1h_1" class="t s3_1">testosterone, but controversy surrounds the role of TST in</div>
<div id="t1i_1" class="t s3_1">the development of new lesions. Haider et al present new</div>
<div id="t1j_1" class="t s3_1">evidence that TST does not increase the incidence of new</div>
<div id="t1k_1" class="t s3_1">lesions. Among the strengths of this study are the large</div>
<div id="t1l_1" class="t s3_1">sample size, the inclusion of three entirely separate cohorts,</div>
<div id="t1m_1" class="t s3_1">the relatively long follow-up period, and the ongoing pro-</div>
<div id="t1n_1" class="t s3_1">spective design. However, the study cohorts represent a</div>
<div id="t1o_1" class="t s3_1">younger population than in the PLCO and ERSPC cohorts,</div>
<div id="t1p_1" class="t s3_1">which complicates efforts to compare the data among these</div>
<div id="t1q_1" class="t s3_1">screening trials.</div>
<div id="t1r_1" class="t v1_1 s3_1">The saturation theory posits that the effect of testos-</div>
<div id="t1s_1" class="t v1_1 s3_1">terone on the prostate is limited by the capacity and</div>
<div id="t1t_1" class="t v1_1 s3_1">concentration of prostate androgen receptors (ARs), and</div>
<div id="t1u_1" class="t v1_1 s3_1">that any testosterone above a certain threshold level will</div>
<div id="t1v_1" class="t v1_1 s3_1">have no effect on the prostate</div>
<div id="t1w_1" class="t v1_1 s7_1">[1]</div>
<div id="t1x_1" class="t v1_1 s3_1">. Marks and colleagues</div>
<div id="t1y_1" class="t v1_1 s7_1">[2]</div>
<div id="t1z_1" class="t v1_1 s3_1">contributedsignificantevidencetothistheorybyfindingthat</div>
<div id="t20_1" class="t v1_1 s3_1">TST increases serum testosterone levels but not intrapro-</div>
<div id="t21_1" class="t v1_1 s3_1">static testosterone levels. More importantly, these investi-</div>
<div id="t22_1" class="t v1_1 s3_1">gators also found no change in prostate histology, the</div>
<div id="t23_1" class="t v1_1 s3_1">expression of testosterone-dependent prostate tissue mar-</div>
<div id="t24_1" class="t v1_1 s3_1">kers (PSA, AR, vascular endothelial growth factor), or the</div>
<div id="t25_1" class="t v1_1 s3_1">incidence of prostate cancer in response to TST</div>
<div id="t26_1" class="t v1_1 s7_1">[2]</div>
<div id="t27_1" class="t v1_1 s3_1">.</div>
<div id="t28_1" class="t v1_1 s3_1">There is of course evidence that testosterone levels do</div>
<div id="t29_1" class="t v1_1 s3_1">correlate with the incidence of prostate cancer. Notably, the</div>
<div id="t2a_1" class="t v1_1 s3_1">Prostate Cancer Prevention Trial (PCPT) and Reduction by</div>
<div id="t2b_1" class="t v1_1 s3_1">Dutasteride of Prostate Cancer Events Trial (REDUCE) both</div>
<div id="t2c_1" class="t v1_1 s3_1">found that use of 5</div>
<div id="t2d_1" class="t v1_1 s8_1">a</div>
<div id="t2e_1" class="t v1_1 s3_1">-reductase inhibitors (which lower</div>
<div id="t2f_1" class="t v1_1 s3_1">dihydrotestosterone levels), despite correlation with a</div>
<div id="t2g_1" class="t v1_1 s3_1">lower incidence of all grades of prostate cancer, was</div>
<div id="t2h_1" class="t v1_1 s3_1">associated with a higher incidence of high-grade prostatic</div>
<div id="t2i_1" class="t v1_1 s3_1">neoplasms</div>
<div id="t2j_1" class="t v1_1 s7_1">[3]</div>
<div id="t2k_1" class="t v1_1 s3_1">. It has been hypothesized that the increase in</div>
<div id="t2l_1" class="t v1_1 s3_1">the incidence of high-grade prostate cancer in patients on</div>
<div id="t2m_1" class="t v1_1 s3_1">5</div>
<div id="t2n_1" class="t v1_1 s8_1">a</div>
<div id="t2o_1" class="t v1_1 s3_1">-reductase inhibitors is because of better ability to detect</div>
<div id="t2p_1" class="t v1_1 s3_1">localized high-grade lesions in a smaller prostate.</div>
<div id="t2q_1" class="t v1_1 s3_1">We have previously published findings that corroborate</div>
<div id="t2r_1" class="t v1_1 s3_1">the absence of an increased risk of prostate cancer with TST.</div>
<div id="t2s_1" class="t v1_1 s3_1">We studied men with hypogonadism who underwent radical</div>
<div id="t2t_1" class="t v1_1 s3_1">prostatectomy for localized prostate cancer and subsequent-</div>
<div id="t2u_1" class="t v1_1 s3_1">ly received TST. Patients on TST had a lower rate of cancer</div>
<div id="t2v_1" class="t v1_1 s3_1">recurrence than an age-matched control group of eugonadal</div>
<div id="t2w_1" class="t v1_1 s3_1">men</div>
<div id="t2x_1" class="t v1_1 s7_1">[4]</div>
<div id="t2y_1" class="t v1_1 s3_1">. In another study we found that hypogonadal</div>
<div id="t2z_1" class="t v1_1 s3_1">patients with prostate cancer treated with external beam</div>
<div id="t30_1" class="t v1_1 s3_1">radiation therapy followed by TST did not have a higher</div>
<div id="t31_1" class="t v1_1 s3_1">recurrence rate than eugonadal men</div>
<div id="t32_1" class="t v1_1 s7_1">[5]</div>
<div id="t33_1" class="t v1_1 s3_1">. In a third study, a</div>
<div id="t34_1" class="t v1_1 s3_1">small series (</div>
<div id="t35_1" class="t v1_1 s5_1">n</div>
<div id="t36_1" class="t v1_1 s3_1">= 13) of hypogonadal men on active surveil-</div>
<div id="t37_1" class="t v1_1 s3_1">lance (Gleason 6,</div>
<div id="t38_1" class="t v1_1 s5_1">n</div>
<div id="t39_1" class="t v1_1 s3_1">= 12; Gleason 7,</div>
<div id="t3a_1" class="t v1_1 s5_1">n</div>
<div id="t3b_1" class="t v1_1 s3_1">= 1) were treated with</div>
<div id="t3c_1" class="t v1_1 s3_1">TST and did not have an increase in mean PSA; on follow-up</div>
<div id="t3d_1" class="t s9_1">EUROPEAN UROLOGY 67 (2015) 1186–1192</div>
<div id="t3e_1" class="t s10_1">available at www.sciencedirect.com</div>
<div id="t3f_1" class="t s10_1">journal homepage: www.europeanurology.com</div>

<form>
<input type="button"  tabindex="5"  id="form1_1" name="75 0 R"  pdfFieldName="75 0 R" onclick="window.location.href='index.html';" style="cursor:pointer;"  title="Page -1" />
<input type="button"  tabindex="3"  id="form1_2" name="73 0 R"  pdfFieldName="73 0 R" onclick="window.location.href='index.html';" style="cursor:pointer;"  title="Page -1" />
<input type="button"  tabindex="1"  id="form1_3" name="71 0 R"  pdfFieldName="71 0 R" onclick="window.location.href='index.html';" style="cursor:pointer;"  title="Page -1" />
<input type="button"  tabindex="4"  id="form1_4" name="74 0 R"  pdfFieldName="74 0 R" onclick="window.location.href='index.html';" style="cursor:pointer;"  title="Page -1" />
<input type="button"  tabindex="6"  id="form1_5" name="76 0 R"  pdfFieldName="76 0 R" onclick="window.location.href='index.html';" style="cursor:pointer;"  title="Page -1" />
<input type="button"  tabindex="2"  id="form1_6" name="72 0 R"  pdfFieldName="72 0 R" onclick="window.location.href='index.html';" style="cursor:pointer;"  title="Page -1" />
<input type="button"  tabindex="7"  id="form1_7" name="77 0 R"  pdfFieldName="77 0 R" onclick="window.open('http://dx.doi.org/10.1016/j.eururo.2015.02.014','_blank');" style="cursor:pointer;" title="http://dx.doi.org/10.1016/j.eururo.2015.02.014" />

</form>
<div id="pg1Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg1"><object width="909" height="1212" data="1/1.svg" type="image/svg+xml" id="pdf1" style="width:909px; height:1212px; background-color:white; -moz-transform:scale(1); z-index: 0;"></object></div>
<!--[if lt IE 9]><script type="text/javascript">
var divCount = 124;
for (var i = 1; i < divCount; i++) {
    var div = document.getElementById("t" + i.toString(36) + "_1");
    if (div !== null) {
        div.style.top = (div.offsetTop * 4) + "px";
        div.style.left = (div.offsetLeft * 4) + "px";
        div.style.zoom = "25%";
    }
}
</script><![endif]-->

</div>
